Package Leaflet: Information for the User
Finasteride IFC1 mg film-coated tablets EFG
Finasteride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
FINASTERIDE is for use by men only and should not be taken by women or children.
Finasteride IFC contains a medicine called finasteride. Finasteride IFC is used for the treatment of early stages of male pattern hair loss (also known as androgenetic alopecia) in men aged 18-41 years. If, after reading this leaflet, you have any questions about male pattern hair loss, you should consult your doctor.
Male pattern hair loss is a common condition thought to be caused by a combination of genetic factors and a specific hormone, called dihydrotestosterone (DHT). DHT contributes to the reduction of the hair growth phase and thinning of the hair.
Finasteride IFC reduces the levels of DHT in the scalp by blocking an enzyme (5-alpha reductase type II) that converts testosterone to DHT. Only men with mild to moderate hair loss may expect benefits from using Finasteride IFC, but not those with complete hair loss or bitemporal recession. In most men treated with Finasteride IFC for 5 years, the progression of hair loss was slowed and at least half of them had some improvement in hair growth.
Do not take Finasteride IFC
Men treated with other medicines containing finasteride, or any other 5α-reductase inhibitor for benign prostatic hyperplasia or for any other condition should not take Finasteride.
Warnings and precautions
Pregnant or potentially pregnant women should not handle crushed or broken tablets. There is a possibility that finasteride may be absorbed through the skin, which could affect the development of the external genitalia of male foetuses. If pregnant women must handle finasteride (the active ingredient), they should inform their doctor.
You should immediately inform your doctor of any changes observed in breast tissue, such as lumps, pain, enlargement of the breast or nipple discharge, as these may be signs of a serious disease such as breast cancer.
Finasteride may affect fertility in males. Male patients who are planning to have a child should consider discontinuing treatment.
Finasteride tablets may affect the results of a blood test called PSA. If you are going to have a blood test to check your prostate, you should inform your doctor that you are taking finasteride.
Determination of prostate-specific antigen (PSA) in serum should be performed before the start of treatment with finasteride and during treatment.
The effect of hepatic impairment on the metabolism of finasteride has not been studied.
Mood changes and depression
Mood changes, such as depressed mood, depression and, less frequently, suicidal thoughts have been reported in patients treated with Finasteride IFC 1 mg film-coated tablets. If you experience any of these symptoms, stop taking Finasteride IFC 1 mg film-coated tablets and consult your doctor as soon as possible.
Using Finasteride IFC with other medicines
Finasteride IFC can be taken normally with other medicines.
However, inform your doctor or pharmacist if you are using or have recently used other medicines, including those obtained without a prescription.
No data are available on the use of Finasteride IFC in combination with topical minoxidil in men with male pattern hair loss.
Taking Finasteride IFC with food and drinks
Finasteride IFC can be taken with or without food.
Pregnancy and breast-feeding
Women should not take Finasteride IFC. Women who are or may be pregnant should not handle crushed or broken finasteride tablets. If a pregnant woman absorbs finasteride through the skin or after oral ingestion, her male foetus may be born with abnormalities of the genital organs. The tablets are coated to prevent contact with finasteride, provided that the tablets are not crushed or broken.
If the patient's partner is or may become pregnant, they should avoid exposure to semen (e.g. by using a condom) or discontinue treatment with finasteride. Consult your doctor or pharmacist before using any medicine.
Driving and using machines
There is no evidence to suggest that finasteride may affect the ability to drive or operate machinery.
Finasteride IFC contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Follow exactly the administration instructions of Finasteride IFC given by your doctor. Consult your doctor or pharmacist if you have any doubts.
Tablet intake:the tablets should be swallowed whole with a little water. They should not be crushed or broken. They can be taken with food or on an empty stomach.
Unless your doctor tells you otherwise, the usual dose for all patients is one tablet per day.
Follow the instructions given by your doctor. Do not change the dose or stop treatment without consulting your doctor first.
Finasteride IFC does not work faster or better if taken more than once a day. To achieve an increase in hair growth or a decrease in hair loss, you must take this medicine every day for 3-6 months or more. Your doctor and you can assess whether treatment with Finasteride IFC has been effective after that. During treatment with Finasteride IFC, there is no need to change your daily hair care routine.
If you consider the effect of Finasteride IFC to be too weak or strong, inform your doctor or pharmacist.
If you take more Finasteride IFC than you should
If you accidentally take too many tablets, inform your doctor or go to a hospital for advice.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount administered.
If you forget to take Finasteride IFC
Do not take a double dose to make up for forgotten doses. Just take the next tablet at the usual time.
If you stop taking Finasteride IFC
In order to maintain the effectiveness of the treatment, it is recommended to use this medicine continuously. Any improvement obtained with respect to hair growth during treatment may disappear 9-12 months after stopping Finasteride IFC.
If you have any doubts about the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The side effects of Finasteride IFC are generally mild and temporary.
Side effects during continuous treatment are usually temporary and disappear when treatment is stopped.
Uncommon (may affect up to 1 in 100 people):
Frequency not known (cannot be estimated from the available data):
Stop taking Finasteride IFC and immediately inform your doctor if you get any of the following symptoms:
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
Reporting of side effects:
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use Finasteride IFC after the expiry date which is stated on the carton after “EXP”. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition ofFinasteride IFC1 mg film-coated tablets
Core of the tablet: lactose monohydrate, microcrystalline cellulose, pregelatinized maize starch, lauryl macrogolglycerides, sodium starch glycolate - Type A (potato), magnesium stearate.
Coating of the tablet: hypromellose, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172) and macrogol 6000.
Appearance of the product and contents of the pack
Finasteride IFC 1 mg film-coated tablets are round, biconvex tablets, reddish-brown in colour and marked with “F1” on one side.
Each pack contains 28, 56, 84 and 98 tablets. Not all pack sizes may be marketed.
Marketing authorisation holder
Industrial Farmacéutica Cantabria, S.A.
Ctra. Cazoña-Adarzo, s/n
39011 Santander – (Spain)
Manufacturer
Actavis Group PTC ehf
Reykjavikurvegi 76-78
IS-220 Hafnarfjördur
Iceland
or
Zentiva k.s.
U Kabelovny 130
102 37 Praha 10
Czech Republic
This medicine is authorised in the Member States of the European Economic Area under the following names:
Spain Finasteride IFC 1 mg film-coated tablets EFG
Italy Carefinast 1 mg film-coated tablets
Date of last revision of this leaflet: August 2018
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/